Announcements Trials
Browse Landscape

Phase

Phase 2 18Phase 1/2 8Phase 1 8Phase 3 4Phase NA 1Phase EARLY_PHASE1 1Phase 4 1

Status

Recruiting 3Active not recruiting 2Withdrawn 1Terminated 1Completed 1

Sponsor Class

OTHER 7INDUSTRY 1

Study Type

Interventional 8

Sponsor

Cancer Type

Genitourinary 8

Conditions

Prostatic Neoplasms 8Metastatic Castration-resistant Prostate Cancer 2Urogenital Neoplasms 1Prostatic Diseases 1PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC) With Prior Exposure to One Prior ARPI Who Are Candidates for Taxane-based Chemotherapy 1Neoplasms by Site 1Neoplasms 1Male Urogenital Diseases 1Genital Neoplasms, Male 1

Interventions

Docetaxel 33Prednisone 28enzalutamide 19Abiraterone Acetate 13pembrolizumab 11gallium 68 PSMA-11 9Leuprolide 9Radiotherapy 8Pluvicto 8Magnetic Resonance Spectroscopy 8Nivolumab 7Estramustine 7abiraterone 6Radiotherapy, Intensity-Modulated 6Goserelin 6Carboplatin 6Biopsy 6olaparib 5cemiplimab 5bicalutamide 5Specimen Handling 5Paclitaxel 5Cyclophosphamide 5temsirolimus 4orteronel 4darolutamide 4cabazitaxel 4acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 4Sirolimus 4Radiosurgery 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

8 trials
RecentStart dateEnrollment
Phase 1/2 × Prostatic Neoplasms × Pluvicto × Clear all
NCT06574880 2026-05-26

STARLiT

Case Comprehensive Cancer Center

Phase 1/2 Recruiting
45 enrolled
Genitourinary

Prostatic Neoplasms

NCT06785636 2026-04-24

P300

Pathos AI, Inc.

Phase 1/2 Recruiting
252 enrolled
Genitourinary

Genital Neoplasms, Male, Neoplasms, Neoplasms by Site, Prostatic Diseases, Prostatic Neoplasms, Urogenital Neoplasms, Male Urogenital Diseases

NCT05113537 2026-04-13

UPLIFT

University of California, San Francisco

Phase 1/2 Recruiting
30 enrolled
Genitourinary

Prostatic Neoplasms

NCT03042468 2025-09-17

Phase I Dose-escalation Study of Fractionated 177Lu-PSMA-617 for Progressive Metastatic CRPC

Weill Medical College of Cornell University

Phase 1/2 Active not recruiting
50 enrolled 19 charts
Genitourinary

Prostatic Neoplasms

NCT04430192 2024-11-08

LuTectomy

Peter MacCallum Cancer Centre, Australia

Phase 1/2 Active not recruiting
20 enrolled
Genitourinary

Prostatic Neoplasms

NCT06329830 2024-09-19

LUNAAR

Baptist Health South Florida

Phase 1/2 Withdrawn
Genitourinary

Prostatic Neoplasms

NCT03545165 2021-08-24

177Lu-J591 and 177Lu-PSMA-617 Combination for mCRPC

Weill Medical College of Cornell University

Phase 1/2 Terminated
6 enrolled 24 charts
Genitourinary

Prostatic Neoplasms

NCT03828838 2019-11-14

Lutetium-177-PSMA-617 in Low Volume Metastatic Prostate Cancer

Radboud University Medical Center

Phase 1/2 Completed
10 enrolled
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡